<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151214</url>
  </required_header>
  <id_info>
    <org_study_id>ALIM-K</org_study_id>
    <nct_id>NCT02151214</nct_id>
  </id_info>
  <brief_title>Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.</brief_title>
  <acronym>ALIM-K</acronym>
  <official_title>Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Paul Strauss</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Jean-Godinot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone (MARSEILLE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In malnourished patients in the palliative phase of cancer, the question is raised of the
      relevance of implementing artificial nutritional assistance instead of oral feeding when this
      is possible.

      Medical prescription and implementation of artificial nutrition at this stage of the illness
      seem less governed by data acquired by science than by subjective reasons (related to
      beliefs, to a cultural or religious tradition, to the symbolic role of eating, to the deeply
      ingrained fear of dying of hunger, to a portrayal of care, etc.) while interacting with
      teams, the patient and his family and relatives.

      And yet, the benefits/risk balance and the effect on quality of life of parenteral nutrition
      in a palliative situation for patients presenting with a normal alimentary tract is poorly
      understood. The discomfort and risks of central venous or nasogastric artificial nutrition
      require that the benefits of artificial nutrition be proven. The nature of these benefits
      relate first and foremost to the quality of life experienced by the patient in such a
      context. Only a controlled randomized study may lead to an optimal palliative nutritional
      management of undernutrition to be determined, and to inform the patient and his/her
      relatives clearly in order for them to express their preferences.

      We hypothesize that abstaining from artificial parenteral central venous nutrition and
      associated hydration for nutritional purposes improves quality of life without significant
      loss of survival compared to implementing artificial nutrition, when considered, in the
      absence of any specific curative treatment in anorexic patients in the palliative phase of
      cancer.

      To test this hypothesis, we propose to carry out a multicenter, prospective, controlled,
      randomized study in order to evaluate the efficacy of implementing parenteral nutrition
      compared to abstaining from doing so on the quality of life of undernourished patients in the
      palliative phase of cancer. The effect on overall survival and the nutritional parameters
      will be evaluated.

      The ALIM K trial will be carried out in 13 centres specializing in supportive and
      onco-hematology care .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2012</start_date>
  <completion_date type="Actual">December 11, 2017</completion_date>
  <primary_completion_date type="Actual">December 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QLQ-C15-Pal to assess Quality of Life through the physical functioning, Global Health Status and fatigue subscales</measure>
    <time_frame>Time until definitive quality of life score deterioration</time_frame>
    <description>The EORTC -The European Organisation for Research and Treatment of Cancer QLQ-C15-Pal - Quality of Life Questionnaire Core 15 Palliative is used.
Physical functioning, global health status and fatigue are compared between the 2 groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QUAL-E Measuring Quality of Life at the end of Life</measure>
    <time_frame>Time until definitive quality of life score deterioration</time_frame>
    <description>Questionaire for patients who believe they are nearing the end of life and comparison between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomization to death</time_frame>
    <description>Comparison of overall survival between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other (non-primary-end point) domains of the QLQ-C15-PAL questionnaire (pain, emotional function, nausea/vomiting, appetite, dyspnea, constipation, and sleep)</measure>
    <time_frame>Time until definitive quality of life score deterioration</time_frame>
    <description>Comparison of other domains of the QLQ-C15-PAL questionnaire between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Time until definitive quality of life score deterioration</time_frame>
    <description>Body weight will be compared between the 2 groups .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Time until definitive quality of life score deterioration</time_frame>
    <description>Body Mass Index will be compared between the 2 groups .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Nutrition Aspect of Cancer</condition>
  <condition>End Stage Cancer</condition>
  <arm_group>
    <arm_group_label>Parenteral nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition will be administered to the patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal per os nutrition</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will eat orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <description>Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted</description>
    <arm_group_label>Parenteral nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria are:

          -  adult patients (aged &gt;18 years) suffering from cancer at the palliative stage, i.e.
             patients in whom the main aim of treatment is to limit pain and discomfort

          -  curative treatment has either been discontinued, or may still be ongoing but with
             little expected benefit in terms of overall survival

          -  patients must already have a functional central venous catheter in place

          -  present malnutrition defined as a body mass index (BMI) &lt;18.5 kg/m² in patients aged
             &lt;70 years or &lt;21 kg/m² in patients aged ≥70 years; or weight loss of 2% in 1 week, 5%
             in 1 month, or 10% in 6 months

          -  patients must have a functional digestive tract

          -  patients able to express themselves easily in French and answer questionnaires

        Exclusion Criteria:

          -  Any condition that prevents orally feeding (especially patients with cancer of the
             upper aero-digestive tract, esophagus, obstructive stomach)

          -  Peritoneal carcinomatosis if it causes symptoms of sub-occlusion or bowel obstruction

          -  Non functional digestive tract (bowel obstruction, tumor compression)

          -  Patients with haematological cancers undergoing bonemarrow transplant,

          -  Life expectancy is less than 1 month

          -  Any contraindications to the parenteral nutrition prescription

          -  Parenteral nutrition that is ongoing or dating from less than one month;

          -  Presence of gastrostomy or jejunostomy;

          -  Persisting sensation of hunger in aphagic patients

          -  Patients participating in another ongoing clinical trial Adult

          -  Patients under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regis Aubry, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palliative Care Unit - CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insitut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pazart L, Cretin E, Grodard G, Cornet C, Mathieu-Nicot F, Bonnetain F, Mercier M, Cuynet P, Bouleuc C, Aubry R; ALIM-K study investigational group. Parenteral nutrition at the palliative phase of advanced cancer: the ALIM-K study protocol for a randomized controlled trial. Trials. 2014 Sep 24;15:370. doi: 10.1186/1745-6215-15-370.</citation>
    <PMID>25248371</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Régis AUBRY</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <keyword>Palliative Phase of Cancer</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Parenteral nutrition</keyword>
  <keyword>Undernutrition</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

